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CD3 (k/uL) 309  117 535  103 1306  403 0.034 0.027
CD3/CD8 (K/uL) 94  42 174  33 325  90 0.021 0.029
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Background: Chronic graft versus host disease (cGVHD) is
associated with mortality, disability and impaired quality of
life. The importance of comorbidities in patients with cGVHD
has not been reported, though this information could be
important for prognostication and tailoring of treatment.
Patients and Methods: We studied 239 patients > 2 years of
age (median 53y, range 11-79) diagnosed with cGVHD by the
NIH consensus criteria and requiring systemic immunosup-
pressive therapy, enrolled in the cGVHDConsortiumat the Fred
HutchinsonCancerResearchCenter (FHCRC).Both incidentand
prevalent cases were included. The Functional Comorbidity
Index (FCI) and the Hematopoietic Cell Transplantation-
speciﬁc Comorbidity Index (HCT-CI) were calculated for all
patients at the time of transplant and cGVHD cohort enroll-
ment. Global cGVHD severity byNIH criteriawasmild or less in
8%, moderate in 54%, and severe in 38% of the patients. Median
follow-up of survivors was 32 months (range 0.6-55.0).
Univariate and multivariate Cox regression models were con-
structed, adjusting for all known and available risk factors
including NIH global severity score at enrollment.
Results: The mean FCI score at the time of transplantation
was 1.8 (range 0-8), increasing to 2.7 (range 0-7) at the time
of cGVHD cohort enrollment (P < .001). The mean HCT-CI
score at the time of transplantation was 2.6 (range 0-8),
increasing to 3.7 (range 0-12) at the time of cohort enroll-
ment (P < .001). Higher FCI scores did not predict risk of
overall or non-relapse mortality. At enrollment, in multi-
variate analyses adjusted for clinical covariates, a statistically
signiﬁcant interaction of the HCT-CI with platelet count was
observed (p¼0.003). Higher HCT-CI scores at enrollment
were associated with an increased risk of overall mortality
when the platelet count was < 100,000/ml (HR 2.01 for 1-pt
increase in HCT-CI: 1.20-3.35, p¼0.01), but not when >
100,000/ml (HR 1.05: 0.90-1.22, p¼0.53). For non-relapse
mortality, higher HCT-CI scores at the time of cGVHD cohort
enrollment were also predictive (HR 1.21:1.04-1.42,P ¼ .01).
Because of overlap between the HCT-CI and the NIH cGVHD
severity scale in the scoring of liver (correlation¼0.61) and
lung (correlation¼0.61) dysfunction, a version of the HCT-CI
that excluded liver and lung variables was tested and
remained signiﬁcantly associated with overall survival in
univariate analysis (HR 1.19,P ¼ .02). Removing the NIH
cGVHD global score from the model did not enhance the
signiﬁcance of the HCT-CI (HR 1.16,P ¼ .02).
Conclusions: A higher comorbidity burden by the HCT-CI at
the time of enrollment into a cGVHD cohort is associated with
an increased risk formortality.We recommend further studies
of comorbidityscoring inpatientswith cGVHDandurge further
investigations that could lead to a mechanistic understanding
of physiologic vulnerability in patients with cGVHD.
464
Interleukin-2 and Granulocyte-Macrophage Colony
Stimulating Factor for Relapse After Allogeneic Stem Cell
Transplantation
Behyar Zoghi 1, Paul J. Shaughnessy 1, Cesar De Las Casas 1,
Ka Wah Chan 2, Veronica H. Jude 2, Robert Sanders 2,
Ashley Simpson 2, Jill MacPherson 1, Lisa McDonald 2,
Julie Luke 2, Carlos Bachier 1. 1 Adult Blood and Marrow
Transplant, Texas Transplant Institute, San Antonio, TX;
2 Pediatric Blood and Marrow Stem Cell Transplant, Texas
Transplant Institute, San Antonio, TX
Strategies for treatment of relapse after allogeneic stem cell
transplant (SCT) include withdrawal of immunosuppressivetherapy and donor lymphocyte infusions (DLI). Trials using
cytokines (CK) have alsodemonstrated allo-immune responses
after allogeneic SCT.We evaluated the role of interleukin-2 (IL-
2) and granulocyte-macrophage colony stimulating factor
(GM-CSF) on patients (pts) relapsing after allogeneic SCT.
Twenty three pts (median age¼50, range 7 months to 66
years) received IL-2 at 1 million units/m2 subcutaneously
(days 8-14) without (n¼13) or with (n¼10) GM-CSF at 500
mcg subcutaneously (days 1-14). Pts received a median of 2
cycles (range 1-4) of IL-2/GM-CSF. SCT sources included:
peripheral blood matched-related (n¼9), or unrelated (n¼7),
bone marrow matched related (n¼1), or unrelated (n¼2) or
umbilical cord blood (n¼4) SCT. Diagnosis included AML
(n¼12), MDS (n¼3), ALL (n¼2), non-Hodgkin's lymphoma
(n¼2) and Hodgkin's disease (n¼1), Chronic Lymphocytic
Leukemia (n¼1). Disease status at SCT included CR1¼3, CR2¼
1; all other pts underwent SCT for primary induction failure or
resistant relapse. Median time from SCT to relapse was 5
months. Pts had receivedDLI (n¼13) or chemotherapy (n¼19)
prior to CK therapy. Response rate after CK therapy was 57 %
(13/23, all CR's). Median overall survival (see ﬁgure) after CK
therapy was 9 months (range¼ 1-47 months). Acute or
chronic graft versus host disease occurred in 13 pts after CK
therapy. The table below summarizes analysis of immune
activation. Values represent means +/- standard error at day
0 (ﬁrst day of GM-CSF), day 8 (prior to start of IL-2) and day 14
(last dayof IL-2 andGM-CSF).P-values arebasedonanalysis of
day 7 versus day 0 and day 14 versus day 0, respectively. Flow
cytometric analysis showed an increase in the numbers of T-
lymphocytes (CD3) and T-cell subsets (CD3/CD8 and CD3/
CD4) as well as an increase in natural killer cells (CD16/56).
Although no differenceswere seen in the number of dendritic
cell subsets, DC1/DC2 ratios decreased with the administra-
tion of GM-CSF/IL-2. Limited (n¼ 4) CD4/FoxP3 analysis did
not show change in absolute numbers with administration of
GM-CSF/IL-2 (data not shown).
In conclusion, CK therapy with IL-2  GM-CSF post SCT is
associated with alloimmune responses. Relapse rate remains
high with most pts relapsing after initial responses.
